New PNH drug shows promise in early trial
NCT ID NCT05889299
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This early-stage study tested a new drug, OMS906, in 15 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The main goal was to check safety and how the body processes the drug, while also looking for early signs that it might help control the disease. Participants either were not on other treatments or were on standard therapy with a poor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Omeros Investigational Site
Kyiv, Ukraine
Conditions
Explore the condition pages connected to this study.